X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

14 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 نوفمبر 2024 06:07:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

13 نوفمبر 2024 06:01:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

24 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أكتوبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

28 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

08 أغسطس 2024 06:01:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أغسطس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024

30 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

27 يونيو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 يونيو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

29 مايو 2024 16:30:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 مايو 2024 08:00:01 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

09 مايو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 مايو 2024 06:01:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

30 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

29 أبريل 2024 06:30:00 بحسب Nasdaq GlobeNewswire